Efficacy and Quality of Life Assessment of ‘Kapiva Dia Free Juice’ Treatment as an Adjuvant for Type 2 Diabetes

Abstract

Background: Diabetes mellitus (DM) is characterized by chronic hyperglycemia, defects in insulin secretion, action, or both, and is fuelled by the obesity epidemic. Conventional medication offers side effects and insufficient glycaemic management in chronic use. Safe and effective adjuvants from the natural source need to be studied clinically. Methods: 30 patients of diabetes mellitus were enrolled in the study for 3 months. The interventional product kapiva dia free juice was administered twice daily along with the conventional antidiabetics. Fasting and post prandial blood glucose were measured every month while HbA1c, serum C-peptide level, BMI, biochemical and hematological investigations on baseline and day 90. Data was analysed using SPSS (version 19). Result: HbA1c was reduced significantly by 11.11% after 90 days of treatment. The percentage of significant reduction in fasting and post prandial blood glucose was 30.05% and 33.11% respectively. BMI was significantly reduced by 2.92% with average weight reduction of 2.17 kg. Insulin resistance was also reduced significantly which was evident by lowered C-Peptide by 28.81%. All the biochemical and hematological parameters were found within normal range and no adverse events were reported related to the investigational product. Conclusion: Kapiva dia free juice is an effective adjuvant treatment in diabetes mellitus which can improve glycemic control, reduce BMI and insulin resistance. This reduces cardiac risk and improves antidiabetic medication effectiveness. All hematological parameters were well within limits in the study which indicates the safety of the product.